Kenneth R. Shroyer, MD, PhD

Kenneth R. Shroyer, MD, PhD
The Marvin Kuschner Professor and Chair
Department of Pathology
President, Stony Brook Pathologists, UFPC
Basic Sciences Tower, Level 9 Rm 140
Stony Brook Medicine
Stony Brook, NY 11794-8691  

Tel:  (631) 444-3000
Fax:  (631) 444-3424
Email: Kenneth.Shroyer@stonybrookmedicine.edu

Personal statement: Dr. Shroyer is Board Certified in Anatomic and Clinical Pathology (1991), with subspecialty certification in Cytopathology (1995). He is a general surgical pathologist with a subspecialty expertise in gynecologic oncology. He also has extensive experience in gynecologic and non-gynecologic cytopathology, including fine needle aspiration cytopathology. Dr. Shroyer pioneered novel methods to improve the accuracy of the cytologic and histologic classification of tumors. He completed his graduate training in Experimental Pathology under the supervision of Dr. Paul K. Nakane, the inventor of the immunoperoxidase method, invented the method of DNP labeling of nucleic acid probes, and was a pioneer in the development of methods for in situ hybridization of mRNAS in the early 1980s. He subsequently authored the first report on the analysis of x-chromosome inactivation in archival tissues as a marker of clonality. Dr. Shroyer contributed to the early validation of tyramide-based signal amplification technology for in situ hybridization and high sensitivity immunohistochemistry and he has been engaged in the development of novel approaches for antibody labeling using nanoparticles for both in vivo imaging and for immunohistochemical applications in collaboration with scientists in biomedical engineering for over ten years. Ongoing areas of investigation in Dr. Shroyer’s laboratory are focusing on the discovery of the mechanistic basis of nuclear keratin 17 as a prognostic biomarker in carcinomas of the female genital tract, pancreas, and other anatomic sites.

MedicalResearch.com Keratin 17 Promotes Cancer Growth and Chemotherapy Resistance
Interview with Kenneth R. Shroyer, September 3, 2015

Peer Reviewed Publications:

 

*including IMAT, Applied Emerging Technologies for Cancer Res., Alliance of Glycobiologists for Detection of Cancer and Cancer Risk, SPOREs in Breast, Cervical, Endometrial, Ovarian, Skin Cancers, Lymphoma, Genitourinary, and Gastrointestinal Cancers and In Vivo Cellular and Molecular Imaging Centers (ICMICs), Cancer Target Discovery and Develop. (CTDD) Network<